Paushak Limited, a member of the **Alembic Group**, is a leading Indian specialty chemicals manufacturer with a niche focus on **Phosgene-based chemistry**. The company serves as a critical intermediary supplier for the pharmaceutical, agrochemical, and performance chemical industries. By transitioning from legacy batch processes to automated, world-scale continuous manufacturing, Paushak is positioning itself as a primary beneficiary of the global **"China Plus One"** sourcing strategy. --- ### **Core Manufacturing Capabilities & Technology Integration** Paushak’s operations are concentrated at its integrated facility in **Vadodara, Gujarat**. The company’s competitive moat is built upon its specialized expertise in handling **Phosgene** and its derivatives—a high-barrier-to-entry segment due to stringent regulatory and safety requirements. * **Process Transformation:** The company is aggressively transitioning from batch processing to **continuous process mode** to enhance throughput, consistency, and safety. * **Automation & Precision:** Operations are managed via **Distributed Control Systems (DCS)**, ensuring automated safety overrides and precision in chemical reactions. * **Operational Excellence:** In **2024**, the company appointed a **Sr. Vice President - Operational Excellence** to oversee manufacturing infrastructure and streamline project execution. * **Maintenance Protocols:** The facility undergoes rigorous annual maintenance; a major planned shutdown was successfully completed in **October 2023** to ensure long-term asset integrity. --- ### **Strategic Growth Roadmap: Capacity Expansion & Modernization** Paushak is executing a multi-phase expansion program to evolve from a domestic player into a global technology leader in Phosgene derivatives. | Project Phase | Status | Strategic Focus | | :--- | :--- | :--- | | **Phase-I** | Operational (since **Q4 FY22**) | Scaled Phosgene and key downstream intermediates; reached rated capacities in **FY24**. | | **Phase-II** | Under Commissioning (**FY26**) | New **Multi-Purpose Plant (MPP)** for advanced derivatives; phased commercial production began in **Jan 2026**. | | **R&D Complex** | Ongoing | New facility dedicated to innovative technology platforms and custom synthesis solutions. | **Key Strategic Levers:** * **Import Substitution:** Paushak has established domestic leadership in select derivatives, significantly reducing India’s reliance on imports and conserving foreign exchange. * **Brand Revitalization:** In **2025**, the company updated its corporate identity (logo and communication) to align with the **Alembic Group** ethos and emphasize customer agility. * **R&D Investment:** The company invested **₹269.85 Lacs** in R&D (FY23) to develop indigenous, environmentally friendly technology platforms. --- ### **Market Dynamics & Sales Performance** While Paushak maintains a strong domestic foothold, its export performance has faced headwinds due to global inventory cycles and pricing pressures. **Sales Distribution (₹ in Lacs):** | Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :---: | :---: | :---: | | **Total Sales** | **20,953.32** | **20,484.39** | **21,077.32** | | **Domestic Sales** | **18,717.95** | **17,770.54** | **16,422.75** | | **Export Sales** | **2,235.37** | **2,713.85** | **4,654.57** | | **Export % of Turnover** | **10.80%** | **13.25%** | **22.24%** | | **National Reach (States)** | **13** | **13** | **10** | | **International Reach (Countries)** | **10** | **10** | **12** | --- ### **Capital Structure & Shareholder Value Enhancement** In 2025, Paushak undertook significant corporate actions to improve share liquidity and expand its investor base. * **Stock Split & Bonus (Sept/Oct 2025):** * Sub-divided equity shares from a face value of **₹10** to **₹5**. * Issued **Bonus Shares** in a **3:1** ratio. * Total equity shares post-action: **2,46,56,912**. * **NSE Listing:** Commenced trading on the **National Stock Exchange (NSE)** on **December 1, 2025**, supplementing its existing **BSE** listing. * **Promoter Holding:** **Nirayu Limited** remains the controlling entity with a **41.15%** stake. * **Financial Flexibility:** In **June 2025**, the Board increased borrowing powers from **₹100 Crores** to **₹750 Crores** to fund aggressive Phase-II and Phase-III expansions. --- ### **Financial Health & Dividend Track Record** The company maintains a conservative balance sheet with a consistent dividend payout policy. | Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | | :--- | :---: | :---: | :---: | :---: | | **Dividend per Share** | **₹20** | **₹20** | **₹17.5** | **₹12** | | **Dividend Percentage** | **200%** | **200%** | **175%** | **120%** | | **Credit Rating (CRISIL)** | **A/Stable** | **A/Stable** | **A-/Positive** | - | * **Credit Risk Management:** Uses an **Expected Credit Loss (ECL)** model. As of March 2023, the allowance for doubtful debts was a marginal **0.67%** of total receivables (**₹35.16 Lacs**). * **Liquidity:** Audits confirm the company’s ability to meet all financial liabilities falling due within **one year**. --- ### **Sustainability & EHS (Environment, Health, and Safety)** As a **Responsible Care®** certified organization, Paushak integrates sustainability into its core operations. * **Energy Mix:** Approximately **33%** of power is sourced from company-owned **windmills**. Boilers utilize a sustainable blend of **biomass and coal**. * **Water & Waste:** Achieved **40% water recycling** via a **Partial Zero Liquid Discharge (ZLD)** system using a **Multiple Effect Evaporator (MEE)**. The company follows a **4R strategy** (Reduce, Reuse, Recycle, Recover). * **Supply Chain:** Over **50%** of raw material procurement by value is certified for social and environmental standards under a **Sustainable Supply Chain Framework**. --- ### **Risk Mitigation & Safety Governance** Operating in the hazardous phosgene sector requires world-class risk management protocols. **Safety Infrastructure:** * **Personnel Protection:** Employees wear specialized tags that change color upon contact with hazardous gases. * **Automated Safety:** The **DCS** system is programmed to trigger immediate plant shutdowns upon sensing any atmospheric hazard. * **Assessment Frameworks:** * **HAZOP/HIRA:** For process and routine operational risk. * **QRA:** For quantitative exposure modeling. * **PSSR:** Mandatory safety verification before any plant restart. **Market Risks:** * **Margin Pressure:** Facing competition from **Chinese overcapacity** and price erosion in the agrochemical sector. * **Mitigation:** The company is pivoting toward higher-value **Pharmaceutical APIs** and specialized **Polymers** to de-risk from commoditized chemical segments.